Sagimet Biosciences (SGMT) News Today → The Best Stock Trading for Less Than $10 Per Share? (From Eagle Publishing) (Ad) Free SGMT Stock Alerts $4.14 -0.65 (-13.57%) (As of 05:22 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 14 at 8:19 AM | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Sagimet Biosciences (NASDAQ:SGMT)HC Wainwright reissued a "buy" rating and set a $32.00 target price on shares of Sagimet Biosciences in a research note on Friday.June 13 at 1:54 AM | americanbankingnews.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives $39.20 Consensus PT from BrokeragesJune 10, 2024 | globenewswire.comSagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of DenifanstatJune 10, 2024 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Buy" by BrokeragesShares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have earned a consensus rating of "Buy" from the seven research firms that are presently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year prJune 9, 2024 | americanbankingnews.comSagimet Biosciences' (SGMT) Market Outperform Rating Reiterated at JMP SecuritiesJune 8, 2024 | marketbeat.comPlatinum Investment Management Ltd. Has $606,000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)Platinum Investment Management Ltd. lowered its position in Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 70.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 111,752 shares of the company's stock after selling 272,161 shares during the period.June 8, 2024 | americanbankingnews.comSagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC WainwrightJune 7, 2024 | marketbeat.comJMP Securities Reaffirms Market Outperform Rating for Sagimet Biosciences (NASDAQ:SGMT)JMP Securities reissued a "market outperform" rating and issued a $48.00 price target on shares of Sagimet Biosciences in a report on Friday.June 6, 2024 | globenewswire.comSagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024May 29, 2024 | markets.businessinsider.comBuy Rating Justified: Sagimet Biosciences’ Undervalued Market Position and Promising NASH Treatment PotentialMay 24, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Stock Rating Reaffirmed by JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $48.00 target price on shares of Sagimet Biosciences in a research report on Friday.May 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sagimet Biosciences on Promising NASH Treatment PotentialMay 16, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Price Target Cut to $23.00 by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group dropped their price objective on shares of Sagimet Biosciences from $27.00 to $23.00 and set a "buy" rating for the company in a report on Thursday.May 16, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT)HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of Sagimet Biosciences in a research report on Thursday.May 16, 2024 | globenewswire.comSagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024May 16, 2024 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by BrokeragesSagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has been given an average rating of "Buy" by the seven ratings firms that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price targMay 16, 2024 | morningstar.comSagimet Biosciences Inc Class A SharesMay 16, 2024 | markets.businessinsider.comSagimet Biosciences: Strong Buy Rating on Robust Financials and Promising NASH Treatment TrialsMay 15, 2024 | investorplace.comSGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024May 15, 2024 | globenewswire.comSagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 7, 2024 | finance.yahoo.comSagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024May 6, 2024 | marketwatch.comSagimet Biosciences Names Thierry Chauche Chief Financial OfficerMay 6, 2024 | finanznachrichten.deSagimet Biosciences Inc.: Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial OfficerMay 6, 2024 | globenewswire.comSagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial OfficerMay 2, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Sagimet Biosciences (SGMT) with Buy RecommendationMay 2, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Coverage Initiated at HC WainwrightHC Wainwright initiated coverage on Sagimet Biosciences in a research note on Thursday. They set a "buy" rating and a $32.00 target price for the company.April 22, 2024 | globenewswire.comSagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024April 13, 2024 | marketbeat.comShort Interest in Sagimet Biosciences Inc. (NASDAQ:SGMT) Expands By 31.3%Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,350,000 shares, a growth of 31.3% from the March 15th total of 1,790,000 shares. Currently, 19.4% of the company's stock are sold short. Based on an average trading volume of 1,710,000 shares, the days-to-cover ratio is presently 1.4 days.March 29, 2024 | insidertrades.comDavid Happel Buys 12,100 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) StockMarch 29, 2024 | marketbeat.comLeerink Partnrs Equities Analysts Boost Earnings Estimates for Sagimet Biosciences Inc. (NASDAQ:SGMT)Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Research analysts at Leerink Partnrs boosted their Q1 2024 earnings per share estimates for shares of Sagimet Biosciences in a research report issued to clients and investors on Tuesday, March 26th. Leerink Partnrs analyst T. Smith now expectMarch 28, 2024 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) CEO David Happel Acquires 12,100 SharesSagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) CEO David Happel bought 12,100 shares of the firm's stock in a transaction on Tuesday, March 26th. The stock was bought at an average price of $5.27 per share, with a total value of $63,767.00. Following the completion of the purchase, the chief executive officer now owns 639,200 shares of the company's stock, valued at $3,368,584. The purchase was disclosed in a legal filing with the SEC, which is available at this link.March 28, 2024 | finance.yahoo.comSagimet Biosciences Inc (SGMT) Reports Full Year 2023 Financial Results: A Close LookMarch 27, 2024 | globenewswire.comSagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor DenifanstatMarch 26, 2024 | marketbeat.comThe Goldman Sachs Group Trims Sagimet Biosciences (NASDAQ:SGMT) Target Price to $27.00The Goldman Sachs Group cut their price target on shares of Sagimet Biosciences from $37.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday.March 25, 2024 | markets.businessinsider.comStrong Buy Recommendation: Sagimet Biosciences’ Unique NASH Drug and Solid Financials Signal Market Growth PotentialMarch 25, 2024 | markets.businessinsider.comSagimet Biosciences: Strong Buy on Robust Financials and Promising NASH Drug TrialsMarch 25, 2024 | msn.comSagimet Biosciences GAAP EPS of -$2.66 beats by $34.65, revenue of $2M in-lineMarch 25, 2024 | marketbeat.comSVB Leerink Initiates Coverage on Sagimet Biosciences (NASDAQ:SGMT)SVB Leerink began coverage on shares of Sagimet Biosciences in a research note on Monday. They issued an "outperform" rating and a $26.00 price target on the stock.March 25, 2024 | globenewswire.comSagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of DirectorsMarch 25, 2024 | globenewswire.comSagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 6, 2024 | marketbeat.comRTW Investments LP Invests $3.52 Million in Sagimet Biosciences Inc. (NASDAQ:SGMT)RTW Investments LP acquired a new stake in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 400,277 shares of the company's stock, valued at approxMarch 5, 2024 | marketbeat.com738,355 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by Rock Springs Capital Management LPRock Springs Capital Management LP purchased a new position in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 738,355 shares of the company's stockMarch 3, 2024 | marketbeat.comShort Interest in Sagimet Biosciences Inc. (NASDAQ:SGMT) Grows By 44.4%Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 1,560,000 shares, an increase of 44.4% from the January 31st total of 1,080,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 12.9% of the company's stock are short sold.February 29, 2024 | globenewswire.comSagimet Biosciences to Participate in Two Upcoming Investor ConferencesFebruary 25, 2024 | benzinga.comSagimet Biosciences Stock (NASDAQ:SGMT) Dividends: History, Yield and DatesFebruary 24, 2024 | msn.comSagimet Biosciences (SGMT) Price Target Increased by 17.19% to 51.00February 23, 2024 | finance.yahoo.comPainful week for retail investors invested in Sagimet Biosciences Inc. (NASDAQ:SGMT) after 22% drop, institutions also suffered lossesFebruary 18, 2024 | marketbeat.com100,000 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by Silverarc Capital Management LLCSilverarc Capital Management LLC acquired a new position in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 100,000 shares of the company's stock, valued at approximately $880,000.February 17, 2024 | morningstar.comSagimet Biosciences Inc Class A Shares SGMTFebruary 7, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) PT Lowered to $46.00JMP Securities reduced their target price on shares of Sagimet Biosciences from $47.00 to $46.00 and set a "market outperform" rating for the company in a research report on Wednesday. Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Your "AI Income Playbook" Awaits... (Ad)Today, he wants to give you his "AI Income Playbook"... FREE of charge! Inside, you'll discover Marc's favorite AI dividend stocks... Complete with their names, ticker symbols, and full breakdown of their massive income potential. Click here now to claim your FREE copy of Marc's AI playbook. SGMT Media Mentions By Week SGMT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMT News Sentiment▼0.540.89▲Average Medical News Sentiment SGMT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMT Articles This Week▼92▲SGMT Articles Average Week Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PepGen News Today Savara News Today Travere Therapeutics News Today Cryoport News Today Heron Therapeutics News Today Annexon News Today SIGA Technologies News Today Y-mAbs Therapeutics News Today Entrada Therapeutics News Today Fulcrum Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMT) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. ...The Freeport Society | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored